Biohaven BHVN
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$14.64M (7 inflow days, 13 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 34.2% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 11.80% to 9.94% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +1,446,859 | 1.1% |
| Capricorn Fund Managers Limited | Hedge Fund | 2026/Q3 | +764,801 | 0.5% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +418,688 | 1.9% |
| Renaissance Technologies Corp. | Hedge Fund | 2026/Q3 | +314,100 | 0.3% |
| Federated Hermes, Inc. | Mutual Fund | 2026/Q3 | +197,087 | 0.3% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +1,164,539 | 0.9% |
| Warren Volles | Individual/Insider | 2026/Q3 | +248,212 | 0.2% |
| Woodline Partners LP | Hedge Fund | 2026/Q3 | +7,359,891 | 5.1% |
| AQR Capital Management | Hedge Fund | 2026/Q3 | +2,152,024 | 2.7% |
| BlackRock | Mutual Fund | 2026/Q3 | +1,988,178 | 8.7% |
| Rubric Capital Management LP | Hedge Fund | 2026/Q3 | +1,721,493 | 1.1% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q3 | +1,343,002 | 2.8% |
| Teachers Insurance and Annuity Association-College Retirement Equities Fund | Mutual Fund | 2026/Q3 | +995,865 | 1.1% |
| Cormorant Asset Management, LP | Hedge Fund | 2026/Q3 | +850,000 | 1.7% |
| Bank of America Corporation | Public Company | 2026/Q3 | +721,765 | 0.9% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 14 Sep 2026 | Kimberly Gentile | Senior Vice President of Clinical Operations | Other Derivative Acquisition | +1,000 | $12.34 | 1,000 |
| 5 Aug 2026 | Infinitum Asset Management, LLC | Initial Statement of Beneficial | +0 | – | 6,250,000 | |
| 8 Jul 2026 | Warren Volles | General Counsel & Chief Legal Officer | Initial Statement of Beneficial | +0 | – | 732,000 |
| 27 Apr 2026 | John Childs | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 | 68,693 |
| 27 Apr 2026 | Julia Gregory | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 | 68,693 |
| 27 Apr 2026 | Robert Hugin | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 | 68,693 |
| 27 Apr 2026 | Gregory Bailey | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 | 68,693 |
| 27 Apr 2026 | Michael Heffernan | Lead Independent Director | Other Derivative Acquisition | +68,693 | $9.61 | 68,693 |
| 27 Apr 2026 | Irina Antonijevic | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 | 68,693 |
| 27 Apr 2026 | Kishan Mehta | Director | Other Derivative Acquisition | +68,693 | $9.61 | 68,693 |
| 16 Mar 2026 | Kishan Mehta | Director | Other Acquisition | +17,342 | – | 22,662 |
| 16 Mar 2026 | Kishan Mehta | Director | Other Disposition | -17,342 | – | 22,662 |
| 26 Feb 2026 | Matthew Buten | Chief Financial Officer | Other Derivative Acquisition | +175,000 | $11.52 | 175,000 |
| 26 Feb 2026 | Vladimir Coric | Chairperson & CEO | Other Derivative Acquisition | +550,000 | $11.52 | 550,000 |
| 26 Feb 2026 | Kimberly Gentile | Senior Vice President of Clinical Operations | Other Derivative Acquisition | +175,000 | $11.52 | 175,000 |
| 26 Feb 2026 | Bruce Car | Chief Innovation Officer | Other Derivative Acquisition | +175,000 | $11.52 | 175,000 |
| 26 Feb 2026 | George Clark | Vice President | Other Derivative Acquisition | +50,000 | $11.52 | 50,000 |
| 4 Jan 2026 | Matthew Buten | Chief Financial Officer | Derivative Exercise and Sale | -2,594 | $9.93 | 195,652 |
| 4 Jan 2026 | Matthew Buten | Chief Financial Officer | Derivative Exercise and Retained | +1,656 | – | 195,652 |
| 4 Jan 2026 | Vladimir Coric | Chairperson & CEO | Derivative Exercise and Sale | -7,430 | $9.93 | 3,849,354 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 15,012,928 | 9.9% | 2.9 |
| 15 Oct 2026 | 17,899,310 | 11.9% | 9.2 |
| 30 Sep 2026 | 19,053,695 | 12.6% | 6.4 |
| 15 Sep 2026 | 20,449,005 | 13.5% | 6.5 |
| 31 Aug 2026 | 19,000,171 | 12.6% | 4.8 |
| 14 Aug 2026 | 17,819,010 | 11.8% | 10.4 |
No comments yet — be the first to weigh in on BHVN.
Sign in to join the discussion.